)
Edge3 Apr 2026
Extra Everything: The Story of Chipotle
Chipotle's story from a single restaurant to a nationwide chain, through crisis and turnaround, built on one of the strongest models in the industry.
TG Therapeutics
TG Therapeutics (TGTX) investor relations material
TG Therapeutics Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary26 Feb, 2026
Executive summary
Achieved $616.3 million in global revenue for 2025, with $594.1 million from U.S. BRIUMVI net sales and $182.7 million in Q4, reflecting 92% year-over-year and 20% sequential growth.
BRIUMVI demonstrated strong physician and patient confidence, supported by six-year open-label extension and ULTIMATE I & II trial data showing nearly 90% of patients free from 24-week confirmed disability progression.
Advanced R&D with phase III ENHANCE study (single-dose consolidation) and subcutaneous BRIUMVI program, targeting pivotal data in late 2025/early 2026 and potential launches in 2027 and 2028.
Expanded commercial footprint, increased prescriber engagement, and launched direct-to-patient initiatives, including a partnership with Christina Applegate for MS education and the "Next In MS" platform.
Expanded BRIUMVI commercialization globally, with approvals in the EU, UK, Switzerland, Australia, Kuwait, and UAE.
Financial highlights
Q4 2025 U.S. BRIUMVI net product revenue was $182.7 million; total Q4 net product revenue was $189.1 million, including $6.4 million ex-U.S.
Full-year 2025 global revenue: $616.3 million; U.S. BRIUMVI: $594.1 million; ex-U.S. product: $12.8 million; royalty/other: $9.4 million.
Operating income for 2025 reached $123.3 million; net income was $447.2 million ($2.77 per diluted share), including a $339.8 million non-recurring tax benefit.
Gross margin slightly below typical due to timing of ex-U.S. sales and a one-time inventory reserve.
R&D expenses: $160.2 million for 2025; SG&A expenses: $232.0 million for 2025.
Outlook and guidance
Reaffirmed 2026 U.S. BRIUMVI net revenue guidance of $825–$850 million; total global revenue guidance of $875–$900 million.
Q1 2026 U.S. revenue expected to grow sequentially to $185–$190 million, with ex-U.S. revenue of $5–$10 million.
Full-year 2026 operating expenses projected at $350 million (excluding non-cash comp), plus $100 million for subcutaneous BRIUMVI manufacturing and startup.
Impact of $100M sub-Q BRIUMVI costs on 2026?
BRIUMVI's differentiation vs. other anti-CD20s?
What non-MS indications for BRIUMVI are planned?
Subcu market share expansion potential
ENHANCE trial's impact on market share
Azer-cel's unmet need in progressive MS
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from TG Therapeutics
- Q2 BRIUMVI sales soared 350%+, driving raised guidance, profitability, and new capital moves.TGTX
Q2 20242 Feb 2026 - BRIUMVI's rapid adoption and pipeline expansion position it for CD20 market leadership.TGTXGoldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026
- Briumvi drives MS market growth, with new patents, pipeline expansion, and a subQ version in development.TGTXJefferies 2024 Global Healthcare Conference1 Feb 2026
- Briumvi Q3 revenue up 230% year-over-year; full-year guidance raised to $300–$305M.TGTXQ3 202417 Jan 2026
- Briumvi's growth accelerates with new formulations, strong sales, and pivotal data expected in 2026.TGTX44th Annual J.P. Morgan Healthcare Conference13 Jan 2026
- BRIUMVI outperforms expectations as SubQ and CAR-T pipeline advances, with new manufacturing underway.TGTX7th Annual Evercore ISI HealthCONx Healthcare Conference12 Jan 2026
- Robust sales, innovation, and pipeline expansion drive leadership in the CD20 market.TGTX43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026
- BRIUMVI outperforms, expands direct-to-patient efforts, and eyes major growth with subQ launch.TGTXCantor Global Healthcare Conference 20255 Jan 2026
- Q1 BRIUMVI sales soared 137%, boosting guidance and signaling strong market momentum.TGTXQ1 202524 Dec 2025
Next TG Therapeutics earnings date
Q1 20264 May, 2026
TG Therapeutics
Next TG Therapeutics earnings date
Q1 20264 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage